Synthesis of pironetin and related analogs: Studies on structure-activity relationships as tubulin assembly inhibitors

被引:42
|
作者
Watanabe, H
Watanabe, H
Usui, T
Kondoh, M
Osada, H
Kitahara, T
机构
[1] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan
[2] RIKEN, Antibiot Lab, Wako, Saitama 3510198, Japan
来源
JOURNAL OF ANTIBIOTICS | 2000年 / 53卷 / 05期
关键词
D O I
10.7164/antibiotics.53.540
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Pironetin (1) and demethylpironetin (2) are potent inhibitors of tubulin assembly. They arrested the mammalian cell cycle in M-phase and showed antitumor activity against a murine tumor cell line, P388 leukemia, transplanted in mice. To investigate the chemical and biological properties of 1, we synthesized several derivatives and investigated the structure-activity relationships. All synthesized derivatives decreased biological activities, such as inhibition of cell cycle progression, and disruption of the microtubule network in situ. The most drastic decrease was observed in 6, 8 and 10. These results suggested that alpha,beta-unsaturated lactone, chirality at the 7-position bearing a hydroxyl group and the terminal portion of the alkyl chain are important for microtubule inhibitory activity of pironetins.
引用
收藏
页码:540 / 545
页数:6
相关论文
共 50 条
  • [31] Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors
    Zhang, Mingzhu
    Jovic, Florence
    Vickers, Troy
    Dyck, Brian
    Tamiya, Junko
    Grey, Jonathan
    Tran, Joe A.
    Fleck, Beth A.
    Pick, Rebecca
    Foster, Alan C.
    Chen, Chen
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (13) : 3682 - 3686
  • [32] Taxol: Synthesis, bioactive conformations, and structure-activity relationships in its analogs
    Zefirova, ON
    Nurieva, EV
    Ryzhov, AN
    Zyk, NV
    Zefirov, NS
    RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, 2005, 41 (03) : 315 - 351
  • [33] Taxol: Synthesis, Bioactive Conformations, and Structure-Activity Relationships in Its Analogs
    O. N. Zefirova
    E. V. Nurieva
    A. N. Ryzhov
    N. V. Zyk
    N. S. Zefirov
    Russian Journal of Organic Chemistry, 2005, 41 : 315 - 351
  • [34] Synthesis and structure-activity relationships of aliphatic isothiocyanate analogs as antibiotic agents
    Li, Deguang
    Shu, Yanan
    Li, Pingliang
    Zhang, Wenbing
    Ni, Hanwen
    Cao, Yongsong
    MEDICINAL CHEMISTRY RESEARCH, 2013, 22 (07) : 3119 - 3125
  • [35] Design, synthesis and structure-activity relationships of mangostin analogs as cytotoxic agents
    Chi, Xiao-Qian
    Zi, Cheng-Ting
    Li, Hong-Mei
    Yang, Liu
    Lv, Yong-Feng
    Li, Jin-Yu
    Hou, Bo
    Ren, Fu-Cai
    Hu, Jiang-Miao
    Zhou, Jun
    RSC ADVANCES, 2018, 8 (72): : 41377 - 41388
  • [36] Synthesis, Insecticidal, Fungicidal Activities and Structure-Activity Relationships of Tschimganin Analogs
    Zhou, Yueting
    Wang, Chunjuan
    Xin, Fang
    Han, Xiaoqiang
    Zhang, Jie
    Sun, Ke
    MOLECULES, 2018, 23 (06):
  • [37] Efficient synthesis of cruentaren A and preparation of analogs for the investigation of structure-activity relationships
    Brandt, Gary E. L.
    Blagg, Brian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [38] Structure-activity studies of some berberine analogs as inhibitors of Toxoplasma gondii
    Krivogorsky, Bogdana
    Pernat, Jennifer A.
    Douglas, Kelsi A.
    Czerniecki, Nikolas J.
    Grundt, Peter
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (08) : 2980 - 2982
  • [39] Oxazolones: New tyrosinase inhibitors; synthesis and their structure-activity relationships
    Khan, Khalid Mohammed
    Mughal, Uzma Rasool
    Khan, Mahmud Tareq Hassan
    Zia-Ullah
    Perveen, Shahnaz
    Choudhary, Muhammad Iqbal
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (17) : 6027 - 6033
  • [40] Antibacterial activity and structure-activity relationships of berberine analogs
    Iwasa, K
    Kamigauchi, M
    Ueki, M
    Taniguchi, M
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1996, 31 (06) : 469 - 478